Özkazanç Ünsal, 2020 - Google Patents
Development of a novel in vitro screening method using genetically modified NK-92 cells against various tumor cellsÖzkazanç Ünsal, 2020
- Document ID
- 1012804384840952343
- Author
- Özkazanç Ünsal D
- Publication year
External Links
- 210000004027 cells 0 title abstract description 455
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7062720B2 (en) | Methods and compositions for cell immunotherapy | |
| US20240279307A1 (en) | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof | |
| JP7601998B2 (en) | Chimeric antigen receptors with BCMA specificity and uses thereof | |
| KR102483822B1 (en) | Tagged chimeric effector molecules and receptors thereof | |
| CN112912105B (en) | Chimeric antigen receptors targeting multiple HLA-G isotypes | |
| EP3194432B1 (en) | Ror1 specific multi-chain chimeric antigen receptor | |
| KR101976882B1 (en) | Method and compositions for cellular immunotherapy | |
| CN111247242A (en) | Chimeric Antigen Receptors (CARs), compositions and methods of use thereof | |
| CN109689694A (en) | Interleukin 2 in conjunction with its receptor IL-2R β, which is used as, to be used to enhance natural killer cells and the active platform of regulatory T cells | |
| CA3125345A1 (en) | Anti-tcr antibody molecules and uses thereof | |
| JP2018518974A (en) | Construction of chimeric antibody receptors (CARs) and methods of use thereof | |
| KR20160068960A (en) | Polyclonal gamma delta t cells for immunotherapy | |
| US20220267425A1 (en) | Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors | |
| JP2024509917A (en) | Method for selective stimulation of T cells in solid tumors using orthogonal IL-2 delivery by oncolytic viruses | |
| US20220195007A1 (en) | Chimeric antigen receptors with cd20 safety switch | |
| TWI865517B (en) | Rituximab-resistant chimeric antigen receptors and uses thereof | |
| Harada et al. | Clinical applications of natural Killer cells | |
| Özkazanç Ünsal | Development of a novel in vitro screening method using genetically modified NK-92 cells against various tumor cells | |
| KR20230019414A (en) | Combination therapy comprising anti-CD39 antibody and adoptive cell therapy | |
| US20240307536A1 (en) | Improved adoptive cell transfer therapy for cancer | |
| RU2816370C2 (en) | Rituximab-resistant chimeric antigen receptors and ways of use thereof | |
| Çelik | A Systemic comparison of different chimeric antigen receptor (car) designs for retargeting of NK-92 cells against tumor antigens | |
| WO2023137069A2 (en) | Bispecific chimeric antigen receptors targeting grp78 and cd123 or grp78 and b7h3 | |
| Cho | Targeting CD155 interactions to enhance natural killer cell therapy for osteosarcoma | |
| Petkova | Targeting and Elimination of T Cell Subpopulations by Chimeric Antigen Receptor-modified T Cells |